½ÃÀ庸°í¼­
»óǰÄÚµå
1585723

äÇ÷ħ ½ÃÀå : À¯Çü, °ÅÁî Å©±â, ¿¬·É´ë, ÃÖÁ¾ »ç¿ëÀÚ ¹× ¿ëµµº° - ¼¼°è ¿¹Ãø(2025-2030³â)

Blood Lancet Market by Type (Home Care Lancet, Safety Lancets, Standard Lancets), Gauze Size (22G, 31 G, Above 38 G), Age Group, End-Users, Application - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 185 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ Ã¤Ç÷ħ ½ÃÀåÀº 2023³â¿¡ 18¾ï 4,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. 2024³â¿¡´Â 20¾ï 4,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 11.09%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 38¾ï 5,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸ÁÀÔ´Ï´Ù.

äÇ÷ħÀº ÁÖ·Î Áø´Ü ¸ñÀûÀ¸·Î Ç÷¾× »ùÇÃÀ» äÃëÇϱâ À§ÇØ ÇǺθ¦ õÀÚÇÏ´Â µ¥ »ç¿ëµÇ´Â ¼ÒÇü ÀÇ·á±â±âÀÔ´Ï´Ù. ±× ¿ëµµ´Â ´ç´¢º´ °ü¸®, ÄÝ·¹½ºÅ×·Ñ °Ë»ç ¹× ±âŸ °Ç°­ ¸ð´ÏÅ͸µ ¿ä±¸ »çÇ× µî ´Ù¾çÇÕ´Ï´Ù. äÇ÷ħÀÇ Çʿ伺Àº Ç÷´ç ÃøÁ¤±â¸¦ »ç¿ëÇÏ´Â ´ç´¢º´ ȯÀÚ¿Í °°ÀÌ Á¤±âÀûÀÎ ¸ð´ÏÅ͸µÀÌ ÇÊ¿äÇÑ È¯ÀÚ¿¡°Ô ÇʼöÀûÀÎ ½Å¼ÓÇϰí ÃÖ¼Ò Ä§½ÀÀûÀΠäÇ÷À» ¿ëÀÌÇÏ°Ô ÇÏ´Â ¿ªÇÒ¿¡ ÀÖ½À´Ï´Ù. Ç÷¾× ·£½ËÀÇ ÁÖ¿ä ÃÖÁ¾ »ç¿ëÀÚ¿¡´Â º´¿ø, Ŭ¸®´Ð, Áø´Ü ½ÇÇè½Ç»Ó¸¸ ¾Æ´Ï¶ó Áý¿¡¼­ ¸¸¼º ÁúȯÀ» °ü¸®ÇÏ´Â °³ÀÎ »ç¿ëÀÚµµ Æ÷ÇԵ˴ϴÙ. ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀº ´ç´¢º´ À¯º´·ü Áõ°¡, ÀÇ·á Áø´Ü ±â¼ú ¹ßÀü, ÀÚ°¡ Áø´Ü ŰƮ¿¡ ´ëÇÑ Àνİú ¼ö¿ä Áõ°¡ÀÔ´Ï´Ù. ÀÌ ½ÃÀåÀÇ »õ·Î¿î ºñÁî´Ï½º ±âȸ·Î´Â Á¤±³Çϰí ÅëÁõÀÌ ÀûÀº ¶õ¼Â µðÀÚÀο¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿Í °Ç°­ ¸ð´ÏÅ͸µ ¾Û°úÀÇ µðÁöÅÐ ÅëÇÕÀ» ÅëÇØ ȯÀÚÀÇ Ã¼°¨µµ¸¦ ³ôÀÌ°í µ¥ÀÌÅÍ ¼öÁý Á¤È®µµ¸¦ ³ôÀÌ´Â °Í µîÀÌ ÀÖ½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁØ ¿¬µµ(2023³â) 18¾ï 4,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2024³â) 20¾ï 4,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2030³â) 38¾ï 5,000¸¸ ´Þ·¯
CAGR(%) 11.09%

±×·¯³ª °¨¿° À§Çè, Æó±â ¹®Á¦, ƯÁ¤ Ç÷¾× »ùÇà ºÐ¼® Àåºñ¿Í ·£½ËÀÇ ÀûÇÕ¼º ÆíÂ÷ µîÀÇ ¹®Á¦°¡ ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ±ÔÁ¦ À庮°ú ´ëü Ç÷¾× »ùÇøµ ¹æ¹ýÀÇ °¡¿ë¼ºµµ Á¦ÇÑ ¿äÀÎÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. º¸´Ù Æí¾ÈÇϰí È¿À²ÀûÀÎ ·£½ËÀÇ °³¹ß°ú µ¥ÀÌÅÍ ¼öÁýÀ» ÀÚµ¿È­Çϰí Á¤È®µµ¸¦ ³ôÀ̱â À§ÇÑ IoT ±â¼ú ÅëÇÕ°ú °°Àº ±â¼ú Çõ½ÅÀº »ó´çÇÑ ¼ºÀå ¿©Áö¸¦ ¼³¸íÇÕ´Ï´Ù. ¶ÇÇÑ, ÅëÁõÀ» ÃÖ¼ÒÈ­ÇÏ°í »ç¿ëÀÚ °æÇèÀ» Çâ»ó½ÃŰ´Â ·£½Ë ¼ÒÀç¿¡ ´ëÇÑ ¿¬±¸´Â Å« ÀáÀç·ÂÀ» °¡Áö°í ÀÖ½À´Ï´Ù.

ÀÌ ½ÃÀåÀº ´ëÇü ÀÇ·á±â±â Á¦Á¶¾÷ü¿Í Áß¼ÒÇü Æ´»õ ½ÃÀå ±â¾÷µéÀÌ ¸ðµÎ Á¸ÀçÇÏ´Â °æÀïÀûÀÎ ½ÃÀåÀ¸·Î Ư¡Áö¾îÁý´Ï´Ù. ±â¾÷µéÀº ģȯ°æ ÀÏȸ¿ë ·£½Ë °³¹ß µî Áö¼Ó°¡´É¼º¿¡ ÃÊÁ¡À» ¸ÂÃß°í, ÀÇ·á ÀÎÇÁ¶ó°¡ °³¼±µÇ°í ÀÖ´Â ½ÅÈï±¹ ½ÃÀå¿¡ ÁøÃâÇÔÀ¸·Î½á ½ÃÀå ±âȸ¸¦ Ȱ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, µðÁöÅÐ Çコ Ç÷§Æû°úÀÇ Á¦ÈÞ¸¦ ÅëÇØ µ¥ÀÌÅÍ ºÐ¼®À» Ȱ¿ëÇÏ¿© »ç¿ëÀÚ Âü¿©¿Í ÄÄÇöóÀ̾𽺠Áؼö¸¦ °­È­ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ : ºü¸£°Ô ÁøÈ­ÇÏ´Â ºí·¯µå ·£½Ë ¼¼°è ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ®À» °ø°³ÇÕ´Ï´Ù.

Ç÷¾× ·£½Ë ¼¼°è ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ëÀ¸·Î ÀÎÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ º¯È­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤À» ³»¸®°í, Àü·«ÀûÀÎ ÀÇ»ç°áÁ¤À» Á¤±³È­Çϸç, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Æ®·»µå¸¦ Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª Àü¹Ý¿¡ °ÉÄ£ ´Ù¾çÇÑ À§ÇèÀ» ÁÙÀÏ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • °³ÀÎÀÇ ´ç´¢º´ À¯º´·ü°ú Ä¡·á °­È­ÀÇ Çʿ伺
    • ¿Â¶óÀÎ À¯Åë ä³ÎÀ» ÅëÇÑ ·£½ËÀÇ ³ôÀº °¡¿ë¼º
    • ´ç´¢º´ °ËÁø Ä·ÆäÀο¡ ´ëÇÑ Á¤ºÎÀÇ ÀÌ´Ï¼ÅÆ¼ºê
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ÇǺΠõÀÚ Á¤È®µµ°¡ ³·°í ¶õ¼ÂÀÇ ¾ÈÀü ¹®Á¦
  • ½ÃÀå ±âȸ
    • ±â¼úÀûÀ¸·Î Áøº¸µÈ ·£½Ë ÀåÄ¡ Çõ½Å
    • ÀçÅÃÀÇ·á¿Í ¿ø°ÝÀÇ·áÀÇ ±Þ¼ÓÇÑ º¸±Þ
  • ½ÃÀå °úÁ¦
    • ·£ÅÏ »ç¿ë ¹× ÆÇ¸Å¿¡ ´ëÇÑ Á¤ºÎÀÇ ¾ö°ÝÇÑ ±ÔÁ¦

Porter's Five Forces: ºí·¯µå ·£½Ë ¼¼°è ½ÃÀå °ø·«À» À§ÇÑ Àü·« µµ±¸

Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â µ¥ Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. PorterÀÇ Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀïÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ ¸ð»öÇϱâ À§ÇÑ ¸íÈ®ÇÑ ¹æ¹ýÀ» ¼³¸íÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÅëÂû·ÂÀ» ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇÏ°í ¾àÁ¡À» º¸¿ÏÇϸç ÀáÀçÀûÀÎ µµÀüÀ» ÇÇÇÔÀ¸·Î½á º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ¼¼°èÀÇ Ã¤Ç÷ħ ½ÃÀå¿¡¼­ÀÇ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ¼¼°èÀÇ Ã¤Ç÷ħ ½ÃÀå ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ ´ã°í ÀÖÀ¸¸ç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀ̰í Àû±ØÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® : ¼¼°èÀÇ Ã¤Ç÷ħ ½ÃÀå °æÀï ±¸µµ ÆÄ¾Ç

Ç÷¾× ·£½Ë ¼¼°è ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ¼¼ºÐÈ­ ¹× ÅëÇÕ Ãß¼¼¸¦ ÆÄ¾ÇÇÏ¿© °ø±Þ¾÷ü°¡ Ä¡¿­ÇÑ °æÀï¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÅëÂû·ÂÀ» Á¦°øÇÕ´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º ºí·¯µå ·£½Ë ¼¼°è ½ÃÀå¿¡¼­ÀÇ º¥´õÀÇ ¼º´É Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ¼¼°è äÇ÷ħ ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀ¸·Î º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× Ãßõ: ºí·¯µå ·£½Ë ¼¼°è ½ÃÀå ¼º°øÀÇ ±æÀ» ±×¸®´Ù.

Ç÷¾× ·£½Ë ¼¼°è ½ÃÀå Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ÀÇ ÀÔÁö¸¦ °­È­ÇϰíÀÚ ÇÏ´Â ±â¾÷¿¡°Ô ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ½Äº°ÇÏ°í °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀº °æÀï ȯ°æÀÇ µµÀüÀ» ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ ü°è¸¦ ±¸ÃàÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÎ¹®¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ½ÃÀå ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõµµ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÎ¹®ÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» ±â¼úÇϰí ÀÖ½À´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸ °³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ, ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5.º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • PorterÀÇ Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå ¼¼°èÀÇ Ã¤Ç÷ħ ½ÃÀå : À¯Çüº°

  • ¼­·Ð
  • ÀçÅÃÄ¡·á ¶õ¼Â
  • ¾ÈÀü ¶õ¼Â
    • ¼öµ¿
    • ¾Ð·Â ÀÛµ¿
  • Ç¥ÁØ ¶õ¼Â

Á¦7Àå ¼¼°èÀÇ Ã¤Ç÷ħ ½ÃÀå : °¡Á¦ »çÀÌÁ

  • ¼­·Ð
  • 22G
  • 31G
  • 38G ÀÌ»ó
  • 22G ÀÌÇÏ

Á¦8Àå ¼¼°èÀÇ Ã¤Ç÷ħ ½ÃÀå : ¿¬·ÉÃþº°

  • ¼­·Ð
  • ¼ºÀÎ
  • ¼Ò¾Æ

Á¦9Àå ¼¼°èÀÇ Ã¤Ç÷ħ ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • ¼­·Ð
  • Ç÷¾×ÀºÇà
  • ÀçÅÃÄ¡·á
  • º´¿ø ¹× Ŭ¸®´Ð

Á¦10Àå ¼¼°èÀÇ Ã¤Ç÷ħ ½ÃÀå : ¿ëµµº°

  • ¼­·Ð
  • ÄÝ·¹½ºÅ×·Ñ °Ë»ç
  • ±Û·çÄÚ¿À½º °Ë»ç
  • Çì¸ð±Û·Îºó °Ë»ç

Á¦11Àå ¾Æ¸Þ¸®Ä«ÀÇ ¼¼°èÀÇ Ã¤Ç÷ħ ½ÃÀå

  • ¼­·Ð
  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦12Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¼¼°èÀÇ Ã¤Ç÷ħ ½ÃÀå

  • ¼­·Ð
  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦13Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ¼¼°èÀÇ Ã¤Ç÷ħ ½ÃÀå

  • ¼­·Ð
  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦14Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®, 2023³â
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023³â
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸®½ºÆ®

  • Abbott Laboratories
  • ACON Laboratories, Inc.
  • AdvaCare Pharma
  • AMBISEA Technology Corp., Ltd.
  • Amkay Products Pvt. Ltd.
  • B. Braun Melsungen AG
  • Becton, Dickinson & Company
  • BioCare Corporation
  • CML BIoTech Ltd.
  • F. Hoffmann-La Roche AG
  • FL MEDICAL s.r.l.
  • Haemonetics Corporation
  • Improve Medical
  • Natus Medical by ARCHIMED
  • Nipro Medical Corporation
  • Owen Mumford Ltd.
  • SARSTEDT AG & Co. KG
  • Shandong Lianfa Medical Plastic Products Co., Ltd.
  • SteriLance Medical(Suzhou) Inc.
  • Terumo Corporation
  • Ypsome AD
LSH

The Blood Lancet Market was valued at USD 1.84 billion in 2023, expected to reach USD 2.04 billion in 2024, and is projected to grow at a CAGR of 11.09%, to USD 3.85 billion by 2030.

Blood lancets are small medical devices used to puncture the skin to obtain a blood sample, primarily for diagnostic purposes. Their application spans diabetes management, cholesterol testing, and other health monitoring needs. The necessity of blood lancets lies in their role in facilitating quick and minimally invasive blood draws, essential for patients requiring regular monitoring, such as diabetics using glucose meters. The primary end-users of blood lancets include hospitals, clinics, diagnostic laboratories, as well as individual users managing chronic illnesses at home. Market growth is driven by an increasing prevalence of diabetes and technological advancements in healthcare diagnostics, as well as growing awareness and demand for self-testing kits. Emerging opportunities in the market include the increasing demand for sophisticated, less painful lancet designs and digital integration with health-monitoring apps to enhance patient experience and data collection accuracy.

KEY MARKET STATISTICS
Base Year [2023] USD 1.84 billion
Estimated Year [2024] USD 2.04 billion
Forecast Year [2030] USD 3.85 billion
CAGR (%) 11.09%

However, challenges such as the risk of infection, disposal issues, and the variability in lancet compatibility with certain blood sample analysis devices can hinder market growth. Regulatory hurdles and the availability of alternative blood sampling methods can also be limiting factors. Innovations such as the development of more comfortable and efficient lancets and the integration of IoT technology to automate data collection and enhance precision offer substantial room for growth. Furthermore, research into lancet materials that minimize pain and improve user experience presents significant potential.

The market is characterized by a competitive landscape with both large healthcare device manufacturers and smaller niche companies. Companies can capitalize on market opportunities by focusing on sustainability, such as developing eco-friendly disposable lancets, and expanding into emerging markets where healthcare infrastructure is being improved. Emphasizing on user education to promote regular testing can further cement market position while advancing partnerships with digital health platforms can leverage data analytics to enhance user engagement and compliance.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Blood Lancet Market

The Blood Lancet Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Prevalence of diabetes among individuals and need for enhanced care
    • High availability of lancet through online distribution channels
    • Government initiatives in diabetes check up campaigns
  • Market Restraints
    • Inaccuracy in skin puncture and safety issues associated with lancet
  • Market Opportunities
    • Innovations of technologically advanced lancet devices
    • Rapid adoption of home based healthcare and telemedicine
  • Market Challenges
    • Stringent government regulations associated with lancet use and marketing

Porter's Five Forces: A Strategic Tool for Navigating the Blood Lancet Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Blood Lancet Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Blood Lancet Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Blood Lancet Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Blood Lancet Market

A detailed market share analysis in the Blood Lancet Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Blood Lancet Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Blood Lancet Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Blood Lancet Market

A strategic analysis of the Blood Lancet Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Blood Lancet Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, ACON Laboratories, Inc., AdvaCare Pharma, AMBISEA Technology Corp., Ltd., Amkay Products Pvt. Ltd., B. Braun Melsungen AG, Becton, Dickinson & Company, BioCare Corporation, CML Biotech Ltd., F. Hoffmann-La Roche AG, FL MEDICAL s.r.l., Haemonetics Corporation, Improve Medical, Natus Medical by ARCHIMED, Nipro Medical Corporation, Owen Mumford Ltd., SARSTEDT AG & Co. KG, Shandong Lianfa Medical Plastic Products Co., Ltd., SteriLance Medical (Suzhou) Inc., Terumo Corporation, and Ypsome AD.

Market Segmentation & Coverage

This research report categorizes the Blood Lancet Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Home Care Lancet, Safety Lancets, and Standard Lancets. The Safety Lancets is further studied across Manually and Pressure Activated.
  • Based on Gauze Size, market is studied across 22G, 31 G, Above 38 G, and Below.
  • Based on Age Group, market is studied across Adult and Pediatrics.
  • Based on End-Users, market is studied across Blood Banks, Home Care, and Hospitals & Clinics.
  • Based on Application, market is studied across Cholesterol Testing, Glucose Testing, and Hemoglobin Testing.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of diabetes among individuals and need for enhanced care
      • 5.1.1.2. High availability of lancet through online distribution channels
      • 5.1.1.3. Government initiatives in diabetes check up campaigns
    • 5.1.2. Restraints
      • 5.1.2.1. Inaccuracy in skin puncture and safety issues associated with lancet
    • 5.1.3. Opportunities
      • 5.1.3.1. Innovations of technologically advanced lancet devices
      • 5.1.3.2. Rapid adoption of home based healthcare and telemedicine
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent government regulations associated with lancet use and marketing
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Blood Lancet Market, by Type

  • 6.1. Introduction
  • 6.2. Home Care Lancet
  • 6.3. Safety Lancets
    • 6.3.1. Manually
    • 6.3.2. Pressure Activated
  • 6.4. Standard Lancets

7. Blood Lancet Market, by Gauze Size

  • 7.1. Introduction
  • 7.2. 22G
  • 7.3. 31 G
  • 7.4. Above 38 G
  • 7.5. Below

8. Blood Lancet Market, by Age Group

  • 8.1. Introduction
  • 8.2. Adult
  • 8.3. Pediatrics

9. Blood Lancet Market, by End-Users

  • 9.1. Introduction
  • 9.2. Blood Banks
  • 9.3. Home Care
  • 9.4. Hospitals & Clinics

10. Blood Lancet Market, by Application

  • 10.1. Introduction
  • 10.2. Cholesterol Testing
  • 10.3. Glucose Testing
  • 10.4. Hemoglobin Testing

11. Americas Blood Lancet Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Blood Lancet Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Blood Lancet Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. ACON Laboratories, Inc.
  • 3. AdvaCare Pharma
  • 4. AMBISEA Technology Corp., Ltd.
  • 5. Amkay Products Pvt. Ltd.
  • 6. B. Braun Melsungen AG
  • 7. Becton, Dickinson & Company
  • 8. BioCare Corporation
  • 9. CML Biotech Ltd.
  • 10. F. Hoffmann-La Roche AG
  • 11. FL MEDICAL s.r.l.
  • 12. Haemonetics Corporation
  • 13. Improve Medical
  • 14. Natus Medical by ARCHIMED
  • 15. Nipro Medical Corporation
  • 16. Owen Mumford Ltd.
  • 17. SARSTEDT AG & Co. KG
  • 18. Shandong Lianfa Medical Plastic Products Co., Ltd.
  • 19. SteriLance Medical (Suzhou) Inc.
  • 20. Terumo Corporation
  • 21. Ypsome AD
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦